Quotes are at least 15-min delayed:2026/08/12 08:43 EDT
Pre Market
|
||||
|
-- 
|
|
|
Regular Hours (Closed)
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.42
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
1.69/--
|
|
Enterprise Value
1.54B
|
| Balance Sheet |
|
Book Value Per Share
17.42
|
| Cash Flow |
|
Cash Flow Yield
0.20
|
| Income Statement |
|
Total Revenue
719.89M
|
|
Operating Revenue Per Share
13.64
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulinactive pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue. |
